RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018.
Fludeoxyglucose (18F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.
- Interesting? Share this article
Other news
LinkedIn post ESRR2024
📢 Important update on EU #GMP Annex 1 at #ESRR2024! The revised EU GMP Annex 1, effecti...
First Patient Dosed with TLX250-CDx in Italy for ccRCC
The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...
GMP-certificate received
Today we received our GMP-certificate!The results of the inspection were excellent and no shortcomin...
Production of novel diagnostic radionuclides in small medical cyclotrons
Employees from RTM and Radboudumc have published a new article: 'Production of novel diagnostic radi...
Interested in a collaboration?
Contact us to discuss the possibilities.